Latigo Biotherapeutics (NASDAQ:LTGO) Rating Increased to Hold at Wall Street Zen

Wall Street Zen upgraded shares of Latigo Biotherapeutics (NASDAQ:LTGO) to a hold rating in a report released on Saturday morning.

Latigo Biotherapeutics Price Performance

Shares of LTGO stock opened at $19.49 on Friday. Latigo Biotherapeutics has a 12-month low of $17.22 and a 12-month high of $22.47.

Insiders Place Their Bets

In other Latigo Biotherapeutics news, Director James B. Tananbaum purchased 140,000 shares of the stock in a transaction dated Monday, August 10th. The shares were bought at an average cost of $18.00 per share, with a total value of $2,520,000.00. Following the completion of the acquisition, the director owned 2,008,024 shares of the company’s stock, valued at approximately $36,144,432. This trade represents a 7.49% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder Foresite Capital Management V, acquired 140,000 shares of the business’s stock in a transaction that occurred on Monday, August 10th. The shares were bought at an average price of $18.00 per share, for a total transaction of $2,520,000.00. Following the completion of the purchase, the insider owned 2,008,024 shares of the company’s stock, valued at approximately $36,144,432. This represents a 7.49% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing.

Latigo Biotherapeutics Company Profile

Latigo Biotherapeutics Inc is a clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medicines designed to stop the transmission of pain without the risk of addiction. Its lead product candidate includes LTG-001. Latigo Biotherapeutics Inc is based in THOUSAND OAKS, Calif.